Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-315: subcutaneous versus intravenous tarlatamab in relapsed extensive-stage small cell lung cancer
2026-525489-23-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Sep 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of tarlatamab in small cell lung cancer (SCLC) (2 arms), sponsored by Amgen. Primary endpoints: Area under the curve from cycle 2 day 1 to day 15 and Predose concentration on cycle 2 day 15. Planned start Sep 2026; status: authorised.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2026-525489-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525489-23-00.